Skip to content

Quality assurance of surgery in the randomised ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1204-1215
Number of pages12
JournalBritish Journal of Surgery
Volume106
Issue number9
Early online date3 Jul 2019
DOIs
DateAccepted/In press - 26 Feb 2019
DateE-pub ahead of print - 3 Jul 2019
DatePublished (current) - 1 Aug 2019

Abstract

Background: The UK Medical Research Council ST03 trial compared perioperative epirubicin, cisplatin and capecitabine (ECX) chemotherapy with or without bevacizumab (B) in gastric and oesophagogastric junctional cancer. No difference in survival was noted between the arms of the trial. The present study reviewed the standards and performance of surgery in the context of the protocol-specified surgical criteria. Methods: Surgical and pathological clinical report forms were reviewed to determine adherence to the surgical protocols, perioperative morbidity and mortality, and final histopathological stage for all patients treated in the study. Results: Of 1063 patients randomized, 895 (84·2 per cent) underwent resection; surgical details were available for 880 (98·3 per cent). Postoperative assessment data were available for 873 patients; complications occurred in 458 (52·5 per cent) overall, of whom 71 (8·1 per cent) developed complications deemed to be life-threatening by the responsible clinician. The most common complications were respiratory (211 patients, 24·2 per cent). The anastomotic leak rate was 118 of 873 (13·5 per cent) overall; among those who underwent oesophagogastrectomy, the rate was higher in the group receiving ECX-B (23·6 per cent versus 9·9 per cent in the ECX group). Pathological assessment data were available for 845 patients. At least 15 nodes were removed in 82·5 per cent of resections and the median lymph node harvest was 24 (i.q.r. 17–34). Twenty-five or more nodes were removed in 49·0 per cent of patients. Histopathologically, the R1 rate was 24·9 per cent (208 of 834 patients). An R1 resection was more common for proximal tumours. Conclusion: In the ST03 trial, the performance of surgery met the protocol-stipulated criteria. Registration number: NCT00450203 (http://www.clinicaltrials.gov).

Documents

Documents

  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1002/bjs.11184 . Please refer to any applicable terms of use of the publisher.

    Final published version, 962 KB, PDF document

    Licence: CC BY

DOI

View research connections

Related faculties, schools or groups